BCX-10013 is under clinical development by BioCryst Pharmaceuticals and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BCX-10013’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCX-10013 is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is administered through oral route and acts by targeting complement factor D.
BioCryst Pharmaceuticals overview
BioCryst Pharmaceuticals (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX9930, BCX9250 and galidesivir (BCX4430). It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.
For a complete picture of BCX-10013’s drug-specific PTSR and LoA scores, buy the report here.